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Abstract
Pre-eclampsia is a major cause of maternal and fetal mortality in pregnancy. The identification of 
genetic variants which predispose to pre-eclampsia demands large DNA collections from affected 
mothers and babies and controls, with reliable supporting phenotypic data. The InterPregGen 
study has assembled a consortium of researchers from Europe, Central Asia and South America 
with the aim of elucidating the genetic architecture of pre-eclampsia. The MoBa collection is 
playing a vital role in this collaborative venture, which has the potential to provide new insights 
into the causes of pre-eclampsia, and provide a rational basis for novel approaches to prevention 
and treatment.
Introduction
The InterPregGen consortium, a multinational collaboration between research groups from 
Europe, Central Asia and South America, is seeking to identify genetic factors which 
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predispose to pre-eclampsia, a quest which has proved challenging to investigators from 
around the world for decades. Pre-eclampsia is the most serious of the hypertensive 
disorders of pregnancy, with an incidence ranging from 2-5% of pregnancies in Western 
Europe and North America to as high as 18% in parts of Africa [1,2]. Advances in maternity 
care have improved the outlook for pre-eclampsia, but it nevertheless remains a significant 
cause of maternal mortality even in countries with well-developed health care provision [3]. 
Exact figures are not available from many developing countries, but on a conservative 
estimate the complications of pregnancy-related hypertension account annually for over 
50,000 maternal deaths worldwide [4]. Pre-eclampsia also has grave effects on the 
developing child, resulting in fetal growth restriction, stillbirth and sudden infant death. 
Expedited premature delivery contributes to perinatal morbidity, and pre-eclampsia is 
associated globally with an estimated 900,000 perinatal deaths annually [4].
The clinical features of pre-eclampsia are maternal hypertension and proteinuria developing 
after the 20th week of gestation; these are manifestations of widespread vascular endothelial 
dysfunction. It is possible that this is a common end point to diverse pathogenetic 
mechanisms, but the two-stage theory is a useful model, supported by observational and 
experimental evidence [5]. In the first stage, inadequate invasion of maternal uterine tissues 
by fetal trophoblast cells results in poor vascular perfusion of the placenta. The second 
stage, maternal endothelial dysfunction, results from the release of damaging factors from 
the placenta into the maternal circulation. One such factor is sFlt-1, a soluble growth factor 
receptor which binds vascular endothelial growth factor (VEGF) and placental growth factor 
(PlGF), interfering with their function in maintaining the integrity of maternal vascular 
endothelium [6]. For the geneticist, an important feature of this model is the involvement of 
two genomes – fetal and maternal – in the pathogenesis of the disorder.
Evidence for genetic factors
Epidemiological studies over the past five decades have provided robust and consistent 
support for the clinical observation that pre-eclampsia runs in families. First degree relatives 
of affected women have a 2- to 3-fold increase in risk of pre-eclampsia [7-10]. Furthermore, 
a pregnancy fathered by a man who was himself born of a pre-eclamptic pregnancy is twice 
as likely to be affected by pre-eclampsia [11]. A study of parous monozygotic and dizygotic 
female twin pairs on the Swedish Twin Register estimated the heritability of pre-eclampsia 
as 54% [12]. Subsequent analysis of over 700,000 births on the Swedish Birth Registry 
estimated pre-eclampsia heritability conferred by maternal genes as 35% (95% CI 33-36%) 
and that due to fetal genes as 20% (95% CI 11-24%), with similar contributions from 
maternally and paternally inherited genes [13]. A complex model of inheritance is likely, 
involving multiple genes with modest individual effect sizes.
These observations justify the search for genetic variants in mothers and babies which 
confer susceptibility to pre-eclampsia. Genetic studies offer an important advantage in the 
identification of novel pathogenetic mechanisms in diseases of pregnancy, as they 
circumvent the practical and ethical challenges of obtaining suitable maternal and fetal 
tissue early in pregnancy, when trophoblastic invasion of maternal tissues occurs; 
investigation of genetic variation in mother and offspring can be conducted on DNA 
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obtained at any time. Furthermore, in a disorder such as pre-eclampsia with a rapidly 
progressive pathophysiology it is often difficult to distinguish between causal factors and 
secondary phenomena resulting from disease processes. Genetic variation which proves to 
be associated with disease is guaranteed to predate the disease process.
Genetic studies of pre-eclampsia
Genome-wide linkage studies of pre-eclampsia, analysing families with two or more 
affected women from Australasia, Iceland, Finland and Holland, have each identified loci 
which appear to show linkage with pre-eclampsia in their populations, but these results have 
not been independently replicated [14-18]. Many candidate genes have been tested for 
association with pre-eclampsia, but in common with the experience in other complex 
disorders, these have generated inconsistent results [19]. Meta-analysis of published 
candidate gene studies has provided some support for genetic association with polymorphic 
loci in genes encoding coagulation factors II and V, the renin-angiotensin system, and 
factors such as methylene tetrahydrofolate reductase (MTHFR) and endothelial nitric oxide 
synthase (eNOS or NOS3) which play a role in maintaining endothelial integrity [20-22]. It 
is nevertheless noteworthy that one published meta-analysis concluded that the quality of the 
evidence from primary genetic association studies is frequently compromised by such 
factors as small study size, or inadequate genotyping quality control [20].
A major cause of the lack of success in identifying susceptibility genes has been the limited 
statistical power of the majority of studies performed to date. It is now apparent that many 
common genetic variants which predispose to complex disorders have individually small 
effect sizes. These variants are therefore difficult to detect by linkage analysis but can be 
detected with much higher power using genetic association study designs [23]. Interest is 
also growing in the contribution made by rare variants with larger effect sizes than those of 
common alleles. In either of these scenarios, the chromosomal locations of disease-
predisposing variants can be detected by genetic association, but only with sufficiently large 
numbers of disease cases to confer adequate statistical power, and only by applying 
rigorously defined thresholds of statistical significance to constrain the rate of false positive 
results [23]. It is also of note that genetic studies in pre-eclampsia have focused on the 
maternal genome with relatively few studies considering the fetal genome, in spite of the 
epidemiological evidence for a fetal contribution to the heritability of the disorder.
The InterPregGen consortium was formed to address these deficiencies, aiming firstly to 
include a sufficiently large number of subjects with rigorously defined pre-eclampsia to 
provide adequate statistical power for association studies to detect genetic variants with 
small effect sizes; secondly, to use genome-wide association screening (GWAS) to scan 
both the maternal and fetal genomes for variants that predispose to pre-eclampsia. Also, the 
majority of larger published genetic studies in pre-eclampsia have been conducted in women 
of European ancestry, where the incidence of pre-eclampsia is amongst the lowest in the 
world. Therefore a further objective of the InterPregGen study was the inclusion of 
populations from different ethnic backgrounds in Europe, Central Asia and South America.
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The InterPregGen study design
Subjects
InterPregGen is making use of several large biobanked DNA collections for studies of pre-
eclampsia in Western Europe. These include the Norwegian Mother and Child Cohort Study 
(MoBa) [24,25]; the Nord-Trøndelag Health Study (HUNT) [26]; FINNPEC (The Finnish 
Genetics of Pre-eclampsia Consortium) [27]; GOPEC (UK Genetics of Pre-eclampsia study) 
[28] and deCODE Genetics’ Icelandic collection [29]. A further 4000 Central Asian mother-
father-baby trios affected by pre-eclampsia are being recruited in Kazakhstan and 
Uzbekistan as part of the study. InterPregGen is also using genome-wide data on 2000 pre-
eclamptic women and 2000 controls from the GenPE study of pre-eclampsia in Colombia, 
South America [30] (Table 1).
The diagnosis of pre-eclampsia is based on an international definition, requiring new-onset 
hypertension (systolic blood pressure ≥ 140 mm Hg; diastolic blood pressure ≥ 90 mm Hg), 
associated with proteinuria (≥ 300 mg/L) after the 20th week of gestation [31]. Recruitment 
of UK, Asian subjects Central Colombian was made at the and time of diagnosis; Finnish 
subjects were recruited prospectively or retrospectively; MoBa subjects are selected from a 
prospectively-recruited pregnancy cohort; Icelandic and HUNT subjects were ascertained by 
linkage to medical registries and scrutiny of obstetric records.
The majority of control subjects are women with no history of hypertension (blood pressure 
<140/90 mm Hg) recruited during pregnancy. For Icelandic and UK subjects control data is 
provided by extensive existing GWAS data from population cohorts of respectively 36000 
and 6000 individuals. Population control data have been used successfully for the 
identification of genetic associations with many complex disorders [32]; providing the 
condition under investigation has a low population frequency (<10%) the advantages of 
extensive control data more than compensate for the small reduction in statistical power 
resulting from misclassification of cases as controls.
All participants in the study have provided informed consent for the use of their samples, or 
those of their babies, in genetic studies. Approval for use of the samples and associated 
clinical data has been obtained from Research Ethics Committees in their country of origin, 
and over-arching approval for the InterPregGen study has been provided by the University 
of Nottingham Research Ethics Committee.
Genome-wide association screening (GWAS)
The study is using genome-wide association screening as the primary strategy for discovery 
of genetic variants which are associated with pre-eclampsia. The principles of GWAS have 
been well-described elsewhere [33]: case and control subjects are genotyped at 600,000 to 
2.5 million single nucleotide polymorphisms (SNPs) selected to capture the majority of 
common genetic variation across the genome. In addition to directly genotyped SNPs, 
thousands of additional genotypes at ungenotyped polymorphisms can be inferred by 
“imputation” algorithms [34] that use correlation (linkage disequilibrium) between alleles at 
nearby SNPs. Imputation requires knowledge of the patterns of linkage disequilibrium and 
for many populations these patterns are readily available from public resources such as 
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HapMap [35] and 1000 Genomes [36]. However genome-wide linkage disequilibrium 
patterns are unavailable for Central Asian populations as they are not represented in publicly 
available databases. To supply this lack of linkage disequilibrium data from Central Asian 
populations, InterPregGen is undertaking whole genome sequencing of 100 Kazakh and 100 
Uzbek subjects.
To maximise the statistical power of the study in a cost-effective way, InterPregGen is 
making use of GWAS data generated in the course of earlier studies in maternal and control 
samples from Iceland, the UK and Colombia. Additional GWAS is being undertaken using 
Illumina genome-wide arrays on offspring of pre-eclamptic pregnancies from Iceland and 
the UK, and also on newly collected maternal-fetal cases and controls from Central Asia. 
GWAS data is therefore available from a total of 7600 maternal cases and 4000 fetal cases 
(Table 1).
GWAS data analysis
For each study population with GWAS genotypes, all directly genotyped and imputed SNPs 
are tested for disease association in pre-eclampsia mothers and babies by logistic regression 
assuming an additive genetic model (SNP genotypes coded 0, 1, or 2). For each study 
population with GWAS genotypes from pre-eclamptic mother-baby pairs, SNPs are also 
tested for evidence that maternal-fetal genotype interaction increases susceptibility to pre-
eclampsia. Allelic odds ratios (OR) provided for each population by logistic regression 
analysis are combined in a meta-analysis to generate an overall OR for each SNP. The 
selection of SNPs for subsequent replication genotyping is based on the results of meta-
analysis, with priority given to those with the lowest p-values. To adjust for the multiple 
statistical tests conducted in the course of GWAS, a meta-analytic p-value below 5×10−8 is 
applied for genome-wide significance (see [37] for an overview of GWAS meta-analysis 
methods).
Rare variants
While the success of recent GWAS studies is impressive, a substantial part of the heritability 
remains unaccounted for and there are reasons to believe that variants with substantial or 
large effects remain undetected [38]. The selection of SNPs for commercial GWAS arrays 
has been largely designed to detect common allelic variants with a population frequency of 
>5%. There is growing interest in the contribution of rarer alleles to heritability of common 
disorders. InterPregGen is addressing this by taking advantage of the unique and extensive 
pedigree information and whole-genome sequencing data available for the Icelandic 
population [39], which allows for reliable detection of variants with 0.1% frequency or 
higher. Significant associations of pre-eclampsia with rare alleles in the Icelandic population 
are then tested by genotyping in other collections.
Follow-up genotyping
A vital component of genetic studies based on genome-wide screening is replication 
genotyping in independent sample collections to confirm positive associations detected by 
genome-wide screening. The European cohorts, MoBa, HUNT and FINNPEC, are providing 
2800 maternal cases, 2400 fetal cases, and 2800 controls for replication studies. The Central 
Morgan et al. Page 5
Nor Epidemiol. Author manuscript; available in PMC 2015 November 11.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Asian collections will provide a further 2000 affected mothers and babies and 2000 controls 
(Table 1). Importantly, in the cohorts used for GWAS and for replication genotyping 
affected mother-baby pairs can be linked for analysis of maternal-fetal gene interactions.
Two related strategies of follow-up genotyping in the replication sets are used. A small 
number of SNPs with the most significant p-values on analysis of GWAS data are 
earmarked for fast track replication genotyping using mass spectrometry or allele-specific 
hybridisation technology. A larger number of SNPs with more modest evidence for 
association with pre-eclampsia will be evaluated by custom-designed genotyping array 
technology in the replication sets.
InterPregGen benefits from the availability of affected mother-father-baby trios in many of 
its cohorts. SNPs which are associated with pre-eclampsia susceptibility in babies are also 
genotyped in all available fathers of pre-eclampsia babies to determine if the ratio of allelic 
transmissions to PE children is different for heterozygous fathers and mothers, to test for 
parent-of-origin (imprinting) effects. The approach for examining parent-of-origin effects in 
Icelandic data will differ, due to the richness of existing Icelandic whole-genome data, 
providing two independent approaches to test for imprinting effects. Through whole-genome 
sequencing of Icelandic individuals, long-range haplotype phasing and parental-origin 
determination the deCODE dataset provides complete information of the parental-origin of 
each allele, without additional genotyping of paternal samples.
Clinical translation
We anticipate that the research effort will identify functional DNA variants, or their proxies, 
which pre-dispose to pre-eclampsia and its complications, leading to enhanced 
understanding of the underlying disease process. InterPregGen will explore the potential for 
translating this information into clinical benefits through risk-profiling and the development 
of novel predictive markers. Currently the prediction of women at high risk of pre-eclampsia 
depends on clinical criteria, including the identification of risk factors at antenatal booking 
[40]. These include primiparity, multiple pregnancy, a previous history of pre-eclampsia, 
obesity, and evidence of hypertension, diabetes or renal disease prior to pregnancy. Even 
amongst these high-risk women only a minority will develop pre-eclampsia (about 15%), 
and better predictive models are required. The potential for genetic profiling in identifying 
individuals at risk of complex disorders has not yet been realised for the majority of 
diseases; this may reflect the incomplete catalogue of genes associated with these disorders. 
In the case of pre-eclampsia, it is possible that both maternal and paternal genotypes are of 
importance. InterPregGen will identify a panel of maternal and paternal genotypes and 
examine their value as “stand-alone” risk markers, and in predictive profiles in combination 
with clinical risk factors. In this regard the availability of extensive and reliable clinical 
information collected during pregnancy will be of vital importance in the evaluation of 
predictive models. The identification of metabolic pathways implicated by susceptibility 
genes in the pathogenesis of pre-eclampsia will highlight metabolites which are likely 
targets for the development of plasma or urinary biomarkers as cost-effective alternatives to 
genetic profiling.
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Role of MoBa in the InterPregGen study
MoBa is a unique collection of samples and data gathered prospectively at the time of 
pregnancy. For researchers into the genetics of complex disorders of pregnancy such as pre-
eclampsia MoBa offers the advantages of a searchable database of reliable clinical 
information which can be used to identify cases and controls which fulfil the inclusion 
criteria of the study with a high degree of confidence. The well-managed biobanking facility 
ensures that DNA of dependable quality is available for genotyping studies from large 
numbers of cases and controls, a vital requirement for adequately powered genetic 
association studies. In contrast to many case-control collections, MoBa includes data and 
DNA samples from the partners and babies of pregnant women, which will enable 
InterPregGen to explore both maternal and fetal genomes, the interactions between maternal 
and fetal gene variants, and the contribution of paternal genes to pre-eclampsia. The 
biobanking expertise of MoBa partners in the InterPregGen study is proving invaluable in 
the discussion of ethical policies, and in the development of procedures for the newly 
formed biobanks in Uzbekistan and Kazakhstan.
Conclusion
The identification of genetic factors which predispose to pre-eclampsia is a large 
undertaking, in which MoBa has a key role. InterPregGen is conducting the largest ever 
genome-wide association screen of maternal and fetal genes and their interactions in this 
disorder, and is also the first with adequate power to investigate the role of genetic 
imprinting (parent-of-origin effect). The ability to compare the genetic architecture of pre-
eclampsia in subjects from three continents may give insights into the source of variation in 
the frequency of the condition across different ethnic groups. The prospects are good for 
novel findings which will ultimately translate into a better understanding and management 
of a condition which remains one of the major killers of pregnant women and their babies 
throughout the world.
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Table 1
Sources and number of samples available for genotyping in the InterPregGen study. GWAS: genome-wide 
association screening.
Biobank
Country of
origin
Maternal
PE cases
Fetal
PE Cases Controls
Samples for GWAS
GOPEC UK 1800 1000 6000
deCODE Iceland 1800 1000 36000
Kazakhstan Kazakhstan 1000 1000 1000
Uzbekistan Uzbekistan 1000 1000 1000
GenPE Colombia 2000 – 2000
Total samples for GWAS 7600 4000 46000
Samples for follow-up genotyping
MoBa Norway 1200 1200 1200
HUNT Norway 1000 600 1000
FINNPEC Finland 600 600 600
Kazakhstan Kazakhstan 1000 1000 1000
Uzbekistan Uzbekistan 1000 1000 1000
Total samples for follow-up 4800 4400 4800
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